News

benzinga_article
2025.11.24 19:59
Shares of IN8bio are trading higher. The company announced consolidated data from its Phase 1 single-center clinical trial of INB-200 and Phase 2 multi-center trial of INB-400 for the treatment of patients with newly diagnosed glioblastoma at 2025 SNO Annual Meeting.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer